Cite
HARVARD Citation
Doble, B. et al. (2017). Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing. Lung cancer. pp. 22-35. [Online].